⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for metastatic sarcomatoid renal cell carcinoma

Every month we try and update this database with for metastatic sarcomatoid renal cell carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney CancerNCT05122546
Advanced Clear ...
Advanced Papill...
Advanced Renal ...
Advanced Sarcom...
Metastatic Clea...
Metastatic Papi...
Metastatic Rena...
Metastatic Sarc...
Stage III Renal...
Stage IV Renal ...
Unresectable Cl...
Unresectable Re...
Cabozantinib S-...
Clostridium but...
Nivolumab
18 Years - City of Hope Medical Center
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney CancerNCT05122546
Advanced Clear ...
Advanced Papill...
Advanced Renal ...
Advanced Sarcom...
Metastatic Clea...
Metastatic Papi...
Metastatic Rena...
Metastatic Sarc...
Stage III Renal...
Stage IV Renal ...
Unresectable Cl...
Unresectable Re...
Cabozantinib S-...
Clostridium but...
Nivolumab
18 Years - City of Hope Medical Center
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney CancerNCT05122546
Advanced Clear ...
Advanced Papill...
Advanced Renal ...
Advanced Sarcom...
Metastatic Clea...
Metastatic Papi...
Metastatic Rena...
Metastatic Sarc...
Stage III Renal...
Stage IV Renal ...
Unresectable Cl...
Unresectable Re...
Cabozantinib S-...
Clostridium but...
Nivolumab
18 Years - City of Hope Medical Center
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsNCT03866382
Bladder Adenoca...
Bladder Clear C...
Bladder Mixed A...
Bladder Neuroen...
Bladder Small C...
Bladder Squamou...
Chromophobe Ren...
Collecting Duct...
Invasive Bladde...
Invasive Bladde...
Invasive Bladde...
Invasive Bladde...
Invasive Bladde...
Invasive Bladde...
Kidney Medullar...
Large Cell Neur...
Malignant Testi...
Malignant Testi...
Metastatic Blad...
Metastatic Blad...
Metastatic Blad...
Metastatic Blad...
Metastatic Blad...
Metastatic Blad...
Metastatic Blad...
Metastatic Blad...
Metastatic Blad...
Metastatic Blad...
Metastatic Chro...
Metastatic Kidn...
Metastatic Mali...
Metastatic Papi...
Metastatic Peni...
Metastatic Pros...
Metastatic Sarc...
Metastatic Uret...
Papillary Renal...
Sarcomatoid Ren...
Stage IV Bladde...
Stage IV Penile...
Stage IV Renal ...
Stage IV Urethr...
Stage IVB Prost...
Urachal Adenoca...
Urethral Clear ...
Bone Scan
Cabozantinib S-...
Computed Tomogr...
Ipilimumab
Magnetic Resona...
Nivolumab
Positron Emissi...
18 Years - National Cancer Institute (NCI)
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: